# A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

> **NCT06363552** · PHASE2 · UNKNOWN · sponsor: **Tianshu Liu** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** SC0191
- **DRUG:** SC0191 + Bevacizumab
- **DRUG:** SC0191 + 5-FU/LV

## Key facts

- **NCT ID:** NCT06363552
- **Lead sponsor:** Tianshu Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05
- **Primary completion:** 2025-04
- **Final completion:** 2025-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363552, "A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06363552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*